Oragenics Shares Are Trading Higher After the Company Announced the Filing Completion for Its ONP-002 Drug in Anticipation of Its Phase IIa Clinical Trail in Concussed Patients.
Oragenics Shares Are Trading Higher After the Company Announced the Filing Completion for Its ONP-002 Drug in Anticipation of Its Phase IIa Clinical Trail in Concussed Patients.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated